Haemonetics has acquired Vivasure, an Ireland-based company developing next-generation technology for percutaneous vessel ...

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...

$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic ...

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, an Ireland-based developer of technology for per ...

Vivasure Medical, a medtech based in Galway’s Parkmore Business Park, has announced it is to be acquired by Haemonetics Corporation, a medical device company located in Boston, Massachusetts. The deal ...

Haemonetics' acquisition of Vivasure adds PerQseal Elite, advancing large-bore closure solutions for TAVR and EVAR markets.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.